Global Hypertension Drugs Market 2016-2020 report is the latest addition to Sandlerresearch.org industry research reports collection, the acceptability of hypertension drugs is expected to rise due to the growing awareness about hypertension and its treatment options. For instance, the National High Blood Pressure Education Program, coordinated by the National Heart, Lung, and Blood Institute of National Institutes of Health, is a cooperative effort among professionals, voluntary health agencies, and state health departments with a goal to cut down death and disability related to high BP through programs of professional, patient, and public education.
The analysts forecast global hypertension drugs market to decline at a CAGR of (0.93) % during the period 2016-2020.
The report, Global Hypertension Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Inquire for more details @ http://www.sandlerresearch.org/inquire-before-buying?rname=53650 .
Main players in the Global Hypertension Drugs Market: Actelion Ltd., AstraZeneca plc, Boehringer Ingelheim GmbH, Daiichi Sankyo Company, Ltd., Novartis AG, and Sanofi SA.Other Prominent Vendors in the market are: Actelion Pharmaceuticals, Arena Pharmaceuticals, Asahi Kasei, Bayer HealthCare, Bellerophon Therapeutics, Bial, CJ HealthCare, Conatus Pharmaceuticals, Daiichi Sankyo, Deka Pharmaceuticals, Dong-A ST, Eiger BioPharmaceuticals, Forest Laboratories, Gilead Sciences, HanAll BioPharma, Hanmi Pharmaceutical, Johnson & Johnson, LG Life Sciences, Lung Biotechnology, Lupin Pharmaceuticals, Mast Therapeutics, Merck, Northern Therapeutics, Ono Pharmaceutical, Pfizer, PhaseBio, Pluristem Therapeutics, Quantum Genomics, Radikal Therapeutics, Reata Pharmaceuticals, Serodus, sigma-tau i.f.r, SteadyMed Therapeutics, Suda, Sun Pharmaceutical Industries, Symplmed Pharmaceuticals, Takeda Pharmaceuticals, United Therapeutics, Valeant Pharmaceuticals, XOMA, and Yuhan.
Further, the report states that patent expiries result in the loss of an exclusive market for a drug, leading to a rapid decline in the sales of the particular drug.
Purchase a copy of Global Hypertension Drugs Market 2016-2020 report @ http://www.sandlerresearch.org/purchase?rname=53650 for US $2500.
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Key buying criteria for drugs that treat hypertension
Exhibit 03: Patent expiries of major cardiovascular drugs
Exhibit 04: Global cardiovascular drugs market by generic and branded drugs sales 2015
Exhibit 05: Top 10 companies in global cardiovascular drugs market 2014
Exhibit 06: Pathophysiology of hypertension
Exhibit 07: Treatment algorithm for hypertension
Exhibit 08: Prevalence of PAH by cause
Exhibit 09: Projected prevalence of CVDs in US 2010-2030 (% of population)
Exhibit 10: Prevalence of hypertension in US population 2010-2030 (% of population)
Exhibit 11: Projected direct and indirect burden of hypertension in US 2010-2030 ($ billions)
Exhibit 12: Projected mortality trend for CVDs globally 2015 and 2030 and more..
Inquire for Discount @ http://www.sandlerresearch.org/discount?rname=53650
Sandlerresearch.org is an online market research store for research reports on multiple industries. These reports provide market analysis, trends and opportunities and forecast about industries that helps to make a right decision for the business.